statistiche ricercatore

Continente	#
NA - Nord America	670
AS - Asia	496
EU - Europa	451
Continente sconosciuto - Info sul continente non disponibili	48
SA - Sud America	46
AF - Africa	5
OC - Oceania	1
Totale	1.717

Nazione	#
US - Stati Uniti d'America	657
SG - Singapore	197
CN - Cina	119
UA - Ucraina	76
GB - Regno Unito	61
IE - Irlanda	58
SE - Svezia	55
IT - Italia	52
VN - Vietnam	50
BR - Brasile	41
RU - Federazione Russa	41
TR - Turchia	39
IN - India	38
FR - Francia	32
DE - Germania	28
BD - Bangladesh	24
FI - Finlandia	18
CZ - Repubblica Ceca	14
JP - Giappone	7
AT - Austria	5
IQ - Iraq	5
CA - Canada	4
ES - Italia	4
HK - Hong Kong	3
JM - Giamaica	3
PK - Pakistan	3
AR - Argentina	2
ID - Indonesia	2
LT - Lituania	2
MX - Messico	2
MY - Malesia	2
NL - Olanda	2
PL - Polonia	2
TT - Trinidad e Tobago	2
ZA - Sudafrica	2
AE - Emirati Arabi Uniti	1
BB - Barbados	1
BE - Belgio	1
CO - Colombia	1
CW - ???statistics.table.value.countryCode.CW???	1
DO - Repubblica Dominicana	1
ET - Etiopia	1
EU - Europa	1
IL - Israele	1
IR - Iran	1
KH - Cambogia	1
LB - Libano	1
MA - Marocco	1
NZ - Nuova Zelanda	1
PH - Filippine	1
PS - Palestinian Territory	1
TN - Tunisia	1
UY - Uruguay	1
VE - Venezuela	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.672

Nome	#
Study of immune alterations in patients with Chronic Fatigue Sindrome with different etiologies	169
Acute urinary retention due to HSV-1: a case report	161
Metabolic modifications in HIV-infected women	154
Cytomegalovirus infection in heart-transplants recipients, in a central region of Italy	150
Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy.	142
Economic evaluation on HIV treatments: The I.Co.N.A. cohort study.	132
Is moderate HIV-viremia associated with a higher risk of clinical progression in HIV-infected people treated with high active antiretroviral therapy.	125
Interruption of highly active antiretroviral therpy in HIV clinical practice.	125
Viral interference between hepatitis B, C and D viruses in dual and triple infections in HIV-positive patients.	123
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.	118
Predictability of sustained virological response to pegylate interferon alpha-2b plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C infection.	111
Mortality from HIV and TB coinfections in higher in Eastern Europe than in Western Europe and Argentina.	108
Risk of developing specific AIDS-defining illness in patients coinfected with HIV and hepatitis C virus with or without cirrhosis.	99
Totale	1.717

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	49	0	0	0	3	10	0	1	6	1	2	9	17
2022/2023	243	16	40	20	27	30	43	10	12	26	6	7	6
2023/2024	99	6	4	3	5	9	31	23	3	1	2	1	11
2024/2025	288	23	56	66	7	2	3	0	23	25	10	31	42
2025/2026	537	56	33	40	57	55	40	78	38	33	44	30	33
2026/2027	36	8	22	6	0	0	0	0	0	0	0	0	0
Totale													1.717